Effects of cepharanthine alone and in combination with fluoropyrimidine anticancer agent, S-l, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice

Anticancer Research

Volumn 29, Issue 4, 2009, Pages 1263-1270

  Harada, Koji ^a   Ferdous, Tarannum ^b   Itashiki, Yasutaka ^a   Takii, Michiyo ^a   Mano, Takamichi ^a   Mori, Yoshihide ^a   Ueyama, Yoshiya ^a  

^a YAMAGUCHI UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

Apoptosis; Cepharanthine; Combination therapy; Nude mice; Oral squamous cell carcinoma; S l; TUNEL; Xenografts

Indexed keywords

5 CHLORO 2,4 DIHYDROXYPYRIDINE PLUS OXONATE POTASSIUM PLUS TEGAFUR; CEPHARANTHINE; DIHYDROPYRIMIDINE DEHYDROGENASE; OROTATE PHOSPHORIBOSYLTRANSFERASE; THYMIDYLATE SYNTHASE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MICRODISSECTION; MOUSE; MOUTH CARCINOMA; NICK END LABELING; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH; TUMOR XENOGRAFT; UPREGULATION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BENZYLISOQUINOLINES; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL PROLIFERATION; DIHYDROURACIL DEHYDROGENASE (NADP); DRUG COMBINATIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; IN SITU NICK-END LABELING; MALE; MICE; MICE, NUDE; MOUTH NEOPLASMS; OROTATE PHOSPHORIBOSYLTRANSFERASE; OXONIC ACID; TEGAFUR; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 64949180436     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Parkin DM, Bray F, Ferlay J and Pisani P: Global cancer statistics, 2002. CA Cancer J Clin 55: 74-108, 2005.
2. Shirasaka T, Shimamoto Y, Ohshimo H, Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a novel form of 5-fluorouracil derivative (S-l) directed to the potentiation of the tumor-selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anticancer Drugs 7: 548-557, 1996.
3. Tatsumi K, Fukushima M, Shirasaka T and Fujii S: Inhibitory effects of pyrimidine, barbituric acid and pyridine derivatives on 5-fluorouracil degradation in rat liver extract. Jpn J Cancer Res 78: 748-755, 1987.
4. Shirasaka T, Shimamoto Y and Fukushima M: Inhibition of oxonic acid on gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004-4009,1993.
5. Shirasaka T, Nakano K, Takechi T, Satake H, Uchida J, Fujioka A, Nakano K, Ohshimo H, Takeda S and Shirasaka T: Antitumor effect of 1 M tegafur-0.4 M 5chloro-2,4-dihydroxypyridine-l M potassium oxonate (S-l) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56: 2602- 2606,1996.
6. Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y and Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-l (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715-1720,1998.
7. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-l, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer 83: 141-145, 2000.
8. Kawahara M, Furuse K, Segawa Y, Yoshimori K, Matsui K, Kudoh S, Hasegawa K and Niitani H: S-l Cooperative Study Group (Lung Cancer Working Group), phase II study of S-l, a novel oral fluorouracil, in advanced non-small cell lung cancer. Br J Cancer 85: 939-943, 2001.
9. Inuyama Y, Kida A, Tsukuda M, Kohno N and Satake B: Late phase II study of S-l in patients with advanced head and neck cancer. Gan To Kagaku Ryoho 28: 1381-1390, 2001.
10. Harada K, Sato M, Ueyama Y, Nagayama M, Hamakawa H, Nagahata S, Yoshimura Y, Osaki T and Ryoke K; Oral Cancer Study Group of Chugoku-Shikoku: Multi-institutional phase II trial of S-l in patients with oral squamous cell carcinoma. Anticancer Drugs 19: 85-90, 2008.
11. Chollet P, Schoffski P, Weigang-Kohler K, Schellens JH, Cure H, Pavlidis N, Grunwald V, De Boer R, Wanders J and Fumoleau P; EORTC Early Clinical Studies Group: Phase II trial with S-l in chemotherapy-naive patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG). Eur J Cancer 39: 1264-1270, 2003.
12. Van den Brande J, Schoffski P, Schellens JH, Roth AD, Duffaud F, Weigang-Kohler K, Reinke F, Wanders J, de Boer RF, Vermorken JB and Fumoleau P; EORTC Early Clinical Studies Group: Early phase II trial of S-l in patients with advanced or metastatic colorectal cancer. Br J Cancer 88: 648-653, 2003.
13. Tomita M, Fujitani K and Aoyagi Y: Synthesis of dl-cepharanthine. Tetrahedron Lett 13: 1201-1206, 1967.
14. Saito R, Tsuchiya S, Ishizuka T, Fueki N, Ezawa K, Minato K, Nakano H, Takise A, Kurihara M and Fueki R: Clinical effects of cepharanthine (Ceph.) on leukopenia by chemotherapy in lung cancer patients. J Jpn Soc Cancer Ther 24: 4587-93,1989.
15. Ono M: Antitumor effect of cepharanthine: activation of regional lymph node lymphocytes by intratumoral administration. Clin Immunol 19: 1061-1064, 1987.
16. Morioka S, Ono M, Tanaka N and Orita K: Synergistic activation of rat alveolar macrophages by cepharanthine and OK-432. Jpn J Cancer Chemother 12: 1407-1407, 1985.
17. Asaumi J, Kawasaki S, Nishikawa K, Kuroda M and Hiraki Y: Effects of hyperthermia and cepharanthine on adriamycin accumulation with change in extracellular pH. Int J Hyperthermia 11: 27-35, 1995.
18. Nishikawa K, Asaumi J, Kawasaki S, Kuroda M, Takeda Y and Hiraki Y: Influence of cepharanthine on the intracelluar accumulation of adriamycin in normal liver cells and spleen cells of mice in vitro and in vivo. Anticancer Res 17: 3617-22, 1997.
19. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Tamai M, Noguchi K, Mizobata S, Arii K and Terasawa H: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Oncology 54: 153-157, 1997.
20. Hotta T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tsunoda T, Noguchi K, Mizobata S and Terasawa H: Synergistic effects of tamoxifen and cepharanthine for circumventing the multidrug resistance. Cancer Lett 707: 117-123, 1996.
21. Furusawa S, Wu J, Fujimura T, Nakano S, Nemoto S, Takayanagi M, Sasaki K and Takayanagi Y: Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Meth Find Exp Clin Pharmacol 20: 87-89, 1998.
22. Harada K, Bando T, Yoshida H and Sato M: Characteristics of antitumour activity of cepharanthine against a human adeno- squamous cell carcinoma cell line. Oral Oncol 37: 643-651, 2001.
23. Kipl. Anticancer Res 23: 1441-1448, 2003.
24. Kipl induces growth arrest and apoptosis in an oral cancer cell line. Oral Oncol 38: 730-736, 2002.
25. Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159, 1987.
26. Mori K, Hasegawa M, Nishida M, Toma H, Fukuda M, Kubota T, Nagasue N, Yamana H, Hirakawa-YS Chung K, Ikeda T, Takasaki K, Oka M, Kameyama M, Toi M, Fujii H, Kitamura M, Murai M, Sasaki H, Ozono S, Makuuchi H, Shimada Y, Onishi Y, Aoyagi S, Mizutani K, Ogawa M, Nakao A, Kinoshita H, Tono T, Imamoto H, Nakashima Y and Manabe T: Expression levels of thymidine phosphorylase and dihydropyrimidine dehydrogenase in various human tumor tissues. Int J Oncol 17: 33-38, 2000.
27. Kurebayashi J, Yamamoto Y, Udagawa K, Okubo S, Fukushima M and Sonoo H: Establishment of enzyme-linked immunosorbent assays for thymidylate synthase and dihydropyriminide dehydrogenase in cancer tissues. Oncol Rep 11: 973-979, 2004.
28. Tsuji T, Sawai T, Takeshita H, Nakagoe T, Hidaka S, Yamaguchi H, Yasutake T, Nagayasu T and Tagawa Y: Tumor dihydropyrimidine dehydrogenase expression is a useful marker in adjuvant therapy with oral fluoropyrimidines after curative resection of colorectal cancer. Cancer Chemother Pharmacol 54: 531-536, 2004
29. Park JS, Young Yoon S, Kim JM, Yeom YI, Kim YS and Kim NS: Identification of novel genes associated with the response to 5-FU treatment in gastric cancer cell lines using a cDNA microarray. Cancer Lett 214: 19-33, 1991.
30. Kamoshida S, Shiogama K, Shimomura R, Inada K, Sakurai Y, Ochiai M, Matuoka H, Maeda K and Tsutsumi Y: Immunohisto- chemical demonstration of fluoropyrimidine-metabolizing enzymes in various types of cancer. Oncol Rep 14: 1223-1230, 2005.
31. Miyoshi Y, Uemura H, Ishiguro H, Kitamura H, Nomura N, Danenberg PV and Kubota Y: Expression of thymidylate synthase, dihydropyrimidine dehydrogenase, thymidine phosphorylase, and orotate phosphoribosyl transferase in prostate cancer. Prostate Cancer Prostatic Dis 8: 260-265, 2005.
32. Salonga D, Danenberg KD, Johnson M, Metzger R, Groshen S, Tsao-Wei DD, Lenz HJ, Leichman CG, Leichman L, Diasio RB and Danenberg PV: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin Cancer Res 6: 1322-1327, 2000.